SCHEMBL3982967

SCHEMBL3982967

O=C(CBr)Nc1ccc(Br)cc1C(O)(c1cccc(Cl)c1)c1cccc(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
LMNA P02545 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MAPT P10636 6/20 0.44
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
HTT P42858 1/20 0.44
KCNQ2 O43526 1/20 0.38
PLCG1 P19174 1/20 0.37
CYP19A1 P11511 1/20 0.36
MAPK1 P28482 1/20 0.36
HPGD P15428 1/20 0.36
IDO1 P14902 1/20 0.36
GAA P10253 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3984353 0.86 ALDH1A1 (0.45) ALDH1A1LMNASMN1; SMN2MAPTMEN1
SCHEMBL3984642 0.78 NPC1 (0.43) ALDH1A1LMNASMN1; SMN2MAPTMEN1
SCHEMBL3984950 0.77 POLB (0.35) ALDH1A1LMNASMN1; SMN2MAPTMEN1
SCHEMBL3982754 0.75 LMNA (0.43) ALDH1A1LMNASMN1; SMN2MAPTMEN1
SCHEMBL4261842 0.72 MAPK1 (0.56) ALDH1A1LMNASMN1; SMN2MAPTMEN1
SCHEMBL3982719 0.69 ALDH1A1 (0.37) ALDH1A1LMNASMN1; SMN2MAPTMEN1
SCHEMBL3981762 0.68 NPC1 (0.42) ALDH1A1LMNASMN1; SMN2MAPTMEN1
SCHEMBL6354673 0.68 NPC1 (0.59) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL4256858 0.68 ALDH1A1 (0.46) ALDH1A1LMNASMN1; SMN2MAPTMEN1
SCHEMBL31306434 0.68 CNR1 (0.46) ALDH1A1LMNASMN1; SMN2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598237-B2 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators WYETH (US) 2009-10-06 US disclosed
US-20080139530-A1 7-Aryl 1,5-Dihydro-4,1-Benzoxazepin-2(3H)-One Derivatives And Their Use As Progesterone Receptor Modulators WYETH (US) 2008-06-12 US disclosed
US-20080113964-A1 7-Aryl 1,5-Dihydro-4,1-Benzoxazepin-2(3H)-One Derivatives and Their Use As Progesterone Receptor Modulators WYETH (US) 2008-05-15 US disclosed
US-7323455-B2 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators WYETH (US) 2008-01-29 US disclosed
WO-2005095366-A1 7-ARYL 1,5-DIHYDRO-4,1-BENZOXAZEPIN-2(3H)-ONE DERIVATIVES AND THEIR USE AS PROGESTERONE RECEPTOR MODULATORS WYETH (US) 2005-10-13 WO disclosed
US-20050215539-A1 7-aryl 1,5-dihydro-4, 1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators WYETH (US) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113964-A1 7-Aryl 1,5-Dihydro-4,1-Benzoxazepin-2(3H)-One Derivatives and Their Use As Progesterone Receptor Modulators PGR, GPER1, PGRMC2 ALDH1A1 1122/4885LMNA 2868/4885SMN1; SMN2 4125/4885
US-20080139530-A1 7-Aryl 1,5-Dihydro-4,1-Benzoxazepin-2(3H)-One Derivatives And Their Use As Progesterone Receptor Modulators PGR, GPER1, PGRMC2 ALDH1A1 1122/4885LMNA 2868/4885SMN1; SMN2 4125/4885
US-20050215539-A1 7-aryl 1,5-dihydro-4, 1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators PGR, GPER1, PGRMC2 ALDH1A1 1122/4885LMNA 2868/4885SMN1; SMN2 4125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.